|
|
|
Novel Platinum Compounds
We have developed two potential drug candidates, BBR 3464 and BBR
3610, that are related to the platinum-based chemotherapy agent Cisplatin.
Cisplatin is one of the most widely used anti-cancer drugs and acts
by binding to DNA, thereby preventing its replication and tumor cell
division. However, while Cisplatin contains a single platinum atom,
our compounds consist of multiple platinum atoms held together by
linking molecules, allowing them to block DNA replication more effectively.
This was born out by preclinical studies, which showed that BBR 3464
and BBR 3610 were far more effective than Cisplatin, in a range of
solid tumors.
However, the higher efficacy of BBR 3464 was not confirmed in recent
phase II studies, which yielded results that were not substantially
different from Cisplatin and other platinum agents currently on
the market. We now believe these disappointing results were due
to the binding and degradation of the compound by human plasma proteins.
Current Research
Our current research is focused on developing new formulations
and delivery systems, which could protect BBR 3464 and BBR 3610
from degradation in human plasma and allow more active drug to reach
the tumor.
Posted July 15, 2005
Copyright © 2004, 2005 Cell Therapeutics, Inc.,
Seattle, WA, USA. All rights reserved. "Making cancer more
treatable"
is a registered mark of CTI. |
|
 |